Gemcitabine is the active ingredient in a drug that is used to treat pancreatic cancer that is advanced or has spread. It is also used together with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine blocks the cell from making DNA and may kill cancer cells. It is a type of antimetabolite
Pediatric and young adult patients whose Hodgkin lymphoma has recurred or is resistant to initial treatment can achieve remission and even cure with secondary treatments.
Novocure announced today results from the second cohort of its phase 2 pilot PANOVA trial studying Tumor Treating Fields (TTFields) in combination with nab-paclitaxel and gemcitabine for the treatment of advanced pancreatic cancer.
Researchers have identified a gatekeeper protein that prevents pancreatic cancer cells from transitioning into a particularly aggressive cell type and also found therapies capable of thwarting those cells when the gatekeeper is depleted.
Researchers from the University of Helsinki have shown that three anti-influenza compounds effectively inhibit Zika virus infection in human cells.
Scientists have shown that a mutation in a gene called Arid1b can cause liver cancer. The gene normally protects against cancer by limiting cell growth, but when mutated it allows cells to grow uncontrollably.
Traditional light microscopy techniques such as confocal and wide-field are diffraction-limited in resolution, which is about 200 nm laterally (in xy) and 500 to 600 nm axially (in z). Features that are closer than the diffraction limit will appear blurred in the image.
We all produce as many as 100,000 different types of cancer cells every day, which are recognized and eliminated by our extraordinarily efficient immune system. However, if something goes wrong with the immune system, and it no longer gets rid of these cells, then that’s when cancerous cells grow and become a problem.
A new immunotherapy treatment has shown dramatic results in treating advanced pancreatic cancer, a deadly cancer that has seen little progress in treatment over the last 20 years.
Scientists at Florida Atlantic University's Harbor Branch Oceanographic Institute found that a deep-water marine sponge collected off of Fort Lauderdale's coast contains leiodermatolide, a natural product that has the ability to inhibit the growth of cancer cells as well as block cancer cells from dividing using extremely low concentrations of the compound.
The monoclonal antibody necitumumab has been approved since February 2016 for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) expressing non-small cell lung cancer (NSCLC) who have not received prior chemotherapy for this condition.
Phase I results published in the Journal of Clinical Oncology suggest that nivolumab, either given alone or alongside platinum-based doublet chemotherapy, could have a role in the first-line treatment of advanced non-small-cell lung cancer.
Researchers at Haukeland University Hospital in Bergen, Norway have combined a laboratory ultrasound technique called "sonoporation" with the commercially-available chemotherapy compound Gemcitabine to increase the porosity of pancreatic cells with microbubbles and to help get the drug into cancer cells where it is needed.
Around 8,800 people in the UK are diagnosed with pancreatic cancer each year. It is known as the UK's deadliest cancer, with a survival rate of just 3 per cent. Chemotherapy and radiotherapy alone are relatively unsuccessful in treating the disease, and while surgery to remove the tumour offers the best chance of survival, most patients are diagnosed when the cancer has already spread to other organs.
Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress.
In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine-based induction chemotherapy, and assessed the effect of erlotinib on survival. Gemcitabine and erlotinib are drugs used to treat cancer.
A common flu virus could be used to overcome patients' resistance to certain cancer drugs -- and improve how those drugs kill cancer cells, according to new research from Queen Mary University of London.
The drug crizotinib (trade name: Xalkori) has been available since 2012 for patients with advanced non-small cell lung cancer (bronchial carcinoma) who have a high activity of the enzyme anaplastic lymphoma kinase (ALK) and have already received another treatment. In November 2015, the approval was extended to first-line treatment.
A promising new discovery by UCLA scientists could lead to a new method of identifying cancer patients that express high levels of an enzyme and are more likely to respond to cancer treatments.
Halozyme Therapeutics, Inc., a biotechnology company developing novel oncology and drug-delivery therapies, today announced the first patient has been dosed in its Halo-301 | Pancreatic study, a Phase 3 clinical trial in previously untreated metastatic pancreatic cancer patients.
A study of obesity and related metabolic changes on bladder cancer incidence and deaths, and a plan to use stem cells to grow novel urinary tubes are among 10 research projects awarded funding by the Johns Hopkins Greenberg Bladder Cancer Institute.